Scientists test drug safety in people with liver damage
NCT ID NCT07282093
Summary
This study aims to understand how liver problems affect how the body processes the cancer drug olverembatinib. Researchers will compare 48 people with varying degrees of liver impairment to healthy volunteers after a single dose. The goal is to gather data to help doctors safely adjust the drug's dose for future patients with liver issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLVEREMBATINIB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Suzhou Medical University
RECRUITINGSuzhou, Jiangsu, 215006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.